Targeting immune checkpoints with blocking monoclonal antibodies (mAb) such as anti-CTLA-4 and anti-PD-1 or anti-PD-L1 has provided clinical benefits for patients with advanced metastatic melanoma, NSCLC, RCC, and several other cancers (164, 165). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.